Primary Hyperoxaluria

This material has been developed and funded by Alnylam Pharmaceuticals. For UK healthcare professionals only.
Date of preparation: March 2026 | NP-UK-00543
Course overview
A practical course for nephrologists, urologists, and allied healthcare professionals involved in the diagnosis and management of rare kidney stone disorders. It focuses on recognising the red flags for primary hyperoxaluria, understanding the diagnostic pathway, supporting effective collaboration between specialties, and knowing how to access specialist treatment through the UK's Rare Disease Collaborative Network.
  • Video modules: 4
  • Expert panel discussion
  • Audience: Kidney specialists
  • Study time:  70 minutes
Launched June 2026
Write your awesome label here.

About the course

This educational programme brings together leading UK nephrologists — adult and paediatric — to guide clinicians through the diagnosis and management of primary hyperoxaluria (PH). Across four modules, the expert panel covers the full clinical picture: from understanding how rare this condition truly is, to the red flags that should prompt investigation, to navigating the differential diagnosis of hyperoxaluria in both children and adults.

The course explores the pathophysiology of PH1, 2, and 3; the evolving role of genetic panel testing versus traditional urinary biochemistry; and how to build effective working relationships with urology colleagues. It also addresses the practical management pathway and how the UK's Rare Disease Collaborative Network supports clinicians in accessing specialist input and high-cost treatments.

Whether you are a trainee or an experienced clinician encountering PH for the first time, this programme provides clear, practical guidance and real-world clinical insight into a condition that is underdiagnosed, increasingly treatable, and no longer a disease without hope.

Course contents

Meet the panel

Authors

Sally Hulton

Consultant Paediatric Nephrologist - 
Great Ormond Street Hospital, London
Dr Hulton is a Consultant Paediatric Nephrologist, specialising in rare inherited kidney disorders, particularly those requiring combined liver-kidney transplantation. She has a special interest in renal metabolic medicine, focusing on inherited renal metabolic disorders. She conducts clinical research for primary hyperoxaluria at both national and international levels. She is past Vice President of the Renal Association, past President of the British Association for Paediatric Nephrology, a Trustee for Kidney Care UK, and Vice Chair of the BCH Ethics Advisory Committee.

Graham Lipkin

Consultant Nephrologist -
Queen Elizabeth Hospital, Birmingham
Dr Lipkin a consultant nephrologist with over 30 years of experience in renal medicine. He has served as past President of the UK Kidney Association, National Co-Chair for Renal GIRFT, and Chair of the Board of Kidney Care UK. He led the development of the Birmingham Centre for Rare Disease and was Clinical Director of Renal Medicine at University Hospital Birmingham. His clinical expertise includes chronic kidney disease, high blood pressure, dialysis, kidney transplantation, and rare kidney diseases. 

Shabbir Moochhala

Consultant Nephrologist -
Royal Free Hospital, London
Dr Moochhala is a consultant nephrologist at the Royal Free Hospital. He has specialist expertise in rare kidney conditions, particularly rare kidney stone diseases, and serves as Principal Investigator for international medical trials in this area. He has extensive experience diagnosing and managing renal tubular disorders, electrolyte imbalances, and Fabry disease, while maintaining a holistic approach to patient care that addresses both kidney-related and broader medical issues. He is the Lead Clinician for the Hyperoxaluria Rare Disease Group.

John Sayer

Clinical Professor of Renal Medicine 
Newcastle University
Prof Sayer is a Clinical Professor of Renal Medicine at Newcastle University and Consultant Nephrologist at the Freeman Hospital’s Renal Services Centre, specialising in inherited kidney diseases and renal stone disorders. He runs regional and family renal genetics clinics and leads several national Renal Rare Diseases Working Groups. His research at Newcastle University centres on renal genetics, cystic kidney disease, ciliopathies, and stone formation, employing advanced genetic and physiological techniques to develop new therapies.